GH1 and acromegaly: In the absence of conclusive guidelines on the treatments of acromegaly patients, guidelines and consensus were published by the scientific societies, suggesting the orientation of the second line treatment according to the patient’s clinical conditions, biology and morphology of the GH secreting pituitary adenomas and to the patient’s comorbidities [2, 5–7].